Network


Latest external collaboration on country level. Dive into details by clicking on the dots.

Hotspot


Dive into the research topics where Gyöngyi Lukács is active.

Publication


Featured researches published by Gyöngyi Lukács.


Journal of Clinical Microbiology | 2004

Differentiation of Rhizomucor Species on the Basis of Their Different Sensitivities to Lovastatin

Gyöngyi Lukács; Tamás Papp; Ildikó Nyilasi; Erzsébet Nagy; Csaba Vágvölgyi

ABSTRACT The opportunistic pathogens Rhizomucor pusillus and Rhizomucor miehei may be agents of frequently fatal mycotic diseases. In the present study, the susceptibilities of 27 clinical and environmental isolates of R. miehei and R. pusillus to lovastatin under different culturing conditions were investigated. Most of the R. miehei strains grew at lovastatin concentrations as high as 64 to 128 μg/ml. In contrast, the inhibitory effect of lovastatin on all of the R. pusillus strains was evident at lovastatin concentrations as low as 1 to 2 μg/ml. A simple and reliable method for species-level differentiation, based on the significantly higher sensitivity of R. pusillus to lovastatin than that of R. miehei, was elaborated. According this, on malt extract agar containing 6 μg of lovastatin/ml, R. pusillus is not able to produce colonies, while R. miehei will form compact colonies.


Journal of Medical Microbiology | 2010

In vitro interactions between primycin and different statins in their effects against some clinically important fungi.

Ildikó Nyilasi; Sándor Kocsubé; Miklós Pesti; Gyöngyi Lukács; Tamás Papp; Csaba Vágvölgyi

The in vitro antifungal activities of primycin (PN) and various statins against some opportunistic pathogenic fungi were investigated. PN completely inhibited the growth of Candida albicans (MIC 64 microg ml(-1)) and Candida glabrata (MIC 32 microg ml(-1)), and was very effective against Paecilomyces variotii (MIC 2 microg ml(-1)), but had little effect on Aspergillus fumigatus, Aspergillus flavus or Rhizopus oryzae (MICs >64 microg ml(-1)). The fungi exhibited different degrees of sensitivity to the statins; fluvastatin (FLV) and simvastatin (SIM) exerted potent antifungal activities against a wide variety of clinically important fungal pathogens. Atorvastatin, rosuvastatin and lovastatin (LOV) had a slight effect against all fungal isolates tested, whereas pravastatin was completely ineffective. The in vitro interactions between PN and the different statins were investigated using a standard chequerboard titration method. When PN was combined with FLV, LOV or SIM, both synergistic and additive effects were observed. The extent of inhibition was higher when these compounds were applied together, and the concentrations of PN and the given statin needed to block fungal growth completely could be decreased by several dilution steps. Similar interactions were observed when the variability of the within-species sensitivities was investigated.


Acta Biologica Hungarica | 2010

Antifungal activity of statins and their interaction with amphotericin B against clinically important Zygomycetes

László Galgóczy; Gyöngyi Lukács; Ildikó Nyilasi; Tamás Papp; Cs. Vágvölgyi

The in vitro antifungal activity of different statins and the combinations of the two most effective ones (fluvastatin and rosuvastatin) with amphotericin B were investigated in this study on 6 fungal isolates representing 4 clinically important genera, namely Absidia, Rhizomucor, Rhizopus and Syncephalastrum . The antifungal effects of statins revealed substantial differences. The synthetic statins proved to be more effective than the fungal metabolites. All investigated strains proved to be sensitive to fluvastatin. Fluvastatin and rosuvastatin acted synergistically and additively with amphotericin B in inhibiting the fungal growth in clinically available concentration ranges. Results suggest that statins combined with amphotericin B have a therapeutic potential against fungal infections caused by Zygomycetes species.


Fems Microbiology Letters | 2007

Interactions between statins and Penicillium chrysogenum antifungal protein (PAF) to inhibit the germination of sporangiospores of different sensitive Zygomycetes

László Galgóczy; Tamás Papp; Gyöngyi Lukács; Éva Leiter; István Pócsi; Csaba Vágvölgyi


Antonie Van Leeuwenhoek International Journal of General and Molecular Microbiology | 2009

Cloning of the Rhizomucor miehei 3-hydroxy-3-methylglutaryl-coenzyme A reductase gene and its heterologous expression in Mucor circinelloides.

Gyöngyi Lukács; Tamás Papp; Ferenc Somogyvári; Árpád Csernetics; Ildikó Nyilasi; Csaba Vágvölgyi


Acta Microbiologica Et Immunologica Hungarica | 2006

PULSED-FIELD GEL ELECTROPHORESIS: A VERSATILE TOOL FOR ANALYSIS OF FUNGAL GENOMES A REVIEW

Gyöngyi Lukács; Miklós Takó; Ildikó Nyilasi


Archive | 2009

Combination compositions comprising antimycotic agents and statins and the use thereof

Csaba Vágvölgyi; Ildikó Nyilasi; Tamás Papp; Miklós Pesti; Gyöngyi Lukács


Acta Microbiologica Et Immunologica Hungarica | 2002

Cloning and sequence analysis of Mucor circinelloides glyceraldehyde-3-phosphate dehydrogenase gene

Klára Ács; Zs. Kasza; Gyöngyi Lukács; Helmut Schwab; Cs. Vágvölgyi


Archive | 2007

A karotinoid termelés genetikai hátterének vizsgálata genetikailag módosított járomspórás gombák segítségével. = Molecular study of the cartenoid biosynthetic pathway using genetically modified zygomycetous fungal strains

Tamás Papp; Gyöngyi Lukács; Ildikó Nyilasi; Miklós Takó


Acta Microbiologica Et Immunologica Hungarica | 2006

CLONING AND PARTIAL SEQUENCE ANALYSIS OF THE RHIZOMUCOR MIEHEI HIGH AFFINITY IRON PERMEASE (FTR1) GENE

Ildikó Nyilasi; Tamás Papp; Gyöngyi Lukács; Erzsébet Nagy; Cs. Vágvölgyi

Collaboration


Dive into the Gyöngyi Lukács's collaboration.

Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Researchain Logo
Decentralizing Knowledge